Abbott (NYSE:ABT) announced today that a new study supports the use of its FreeStyle Libre 2 continuous glucose monitor (CGM).
The study, published in The New England Journal of Medicine, evaluated adults with type 1 diabetes and suboptimal glycemic control. It demonstrated significant reductions in glycated hemoglobin (HbA1c) compared to self-monitoring of blood glucose. Subjects sustained HbA1c reductions for the study duration of 24 weeks.
Abbott also reported links between FreeStyle Libre 2 and improvements in participant-reported quality of life outcomes. Those include overall satisfaction and reduction in burden associated with glucose monitoring.
Get the full story at our sister site, Drug Delivery Business News.